Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUV-422 in Advanced Solid Tumors
NCT04541225Phase 1Terminated
- Sponsor
- Nuvation Bio
- Start
- Dec 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inixaciclib in glioma, breast cancer and metastatic castration-resistant prostate cancer (mCRPC), sponsored by Nuvation Bio. Primary endpoints: Safety and tolerability of NUV-422 at 28 days and Recommended Phase 2 Dose at 28 days. Started Dec 2020; status: terminated.
02
Drugs
inixaciclib
03
Conditions
gliomabreast cancermetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04541225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541225.